Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST Larotrectinib substudy for NTRK-rearranged advanced cancers
ACTRN12619001147178Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of larotrectinib in cancer and Nonhematologic neoplasms, sponsored by The University of Sydney. Primary endpoint: Disease control. Started Nov 2020; status: completed.
02
Drugs
larotrectinib
03
Conditions
cancerNonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12619001147178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001147178.